Share
𝕏 Facebook LinkedIn

[Preliminary clinical comparison of HLF and ELF regimen in the treatment of advanced gastric carcinoma in middle-aged and elderly patients].

PAPER pubmed Zhonghua zhong liu za zhi [Chinese journal of oncology] 2000 Other Effect: mixed Evidence: Low

Abstract

OBJECTIVE: To observe the therapeutic effects and toxicity of HLF (hydroxycamptothecin HCPT/leucovorin LV/fluorouracil 5-Fu) regimen and ELF (etoposide VP-16/LV/5-Fu) regimen in middle-aged and elderly patients with advanced gastric carcinoma. METHODS: A group of twenty-five cases were treated with HLF regimen, and the other group of 23 cases were treated with ELF regimen. RESULTS: Of the 25 cases treated with HLF regimen, there was no complete remission (CR), but there were 12 partial response (PR), 11 no response (NC), and 2 had progressive disease (PD). The response rate (RR) was 48.0%. Of the 23 patients treated with ELF regimen, there was no CR, there were 9 PR, 11 NC, and 3 PD. The RR was 39.1% (P > 0.05). The main toxicity was myelosuppression and stomatocace. Grade III-IV stomatocace in HLF regimen group (68.0%) was more commonly seen than that in ELF regimen group (39.1%, P < 0.05). There was no cardiac or renal toxicity observed. CONCLUSION: HLF regimen is promising for treatment of advanced gastric carcinoma in middle-aged and elderly patients with the merits of low toxicity affecting heart, kidney and bladder except stomatocace, which is worthy of further clinical trial.

AI evidence extraction

At a glance
Study type
Other
Effect direction
mixed
Population
Middle-aged and elderly patients with advanced gastric carcinoma
Sample size
48
Exposure
Evidence strength
Low
Confidence: 74% · Peer-reviewed: yes

Main findings

In 25 patients treated with HLF, response rate was 48.0% (0 CR, 12 PR, 11 NC, 2 PD). In 23 patients treated with ELF, response rate was 39.1% (0 CR, 9 PR, 11 NC, 3 PD); the difference was not statistically significant (P > 0.05). Grade III–IV stomatocace was more common with HLF (68.0%) than ELF (39.1%, P < 0.05); no cardiac or renal toxicity was observed.

Outcomes measured

  • Tumor response (CR/PR/NC/PD; response rate)
  • Toxicity (myelosuppression, stomatocace; grade III–IV stomatocace)
  • Cardiac toxicity
  • Renal toxicity

Limitations

  • No randomization described in abstract
  • Small sample size (n=48)
  • No survival outcomes reported (e.g., overall survival, progression-free survival)
  • Limited toxicity detail beyond selected adverse events
View raw extracted JSON
{
    "study_type": "other",
    "exposure": {
        "band": null,
        "source": null,
        "frequency_mhz": null,
        "sar_wkg": null,
        "duration": null
    },
    "population": "Middle-aged and elderly patients with advanced gastric carcinoma",
    "sample_size": 48,
    "outcomes": [
        "Tumor response (CR/PR/NC/PD; response rate)",
        "Toxicity (myelosuppression, stomatocace; grade III–IV stomatocace)",
        "Cardiac toxicity",
        "Renal toxicity"
    ],
    "main_findings": "In 25 patients treated with HLF, response rate was 48.0% (0 CR, 12 PR, 11 NC, 2 PD). In 23 patients treated with ELF, response rate was 39.1% (0 CR, 9 PR, 11 NC, 3 PD); the difference was not statistically significant (P > 0.05). Grade III–IV stomatocace was more common with HLF (68.0%) than ELF (39.1%, P < 0.05); no cardiac or renal toxicity was observed.",
    "effect_direction": "mixed",
    "limitations": [
        "No randomization described in abstract",
        "Small sample size (n=48)",
        "No survival outcomes reported (e.g., overall survival, progression-free survival)",
        "Limited toxicity detail beyond selected adverse events"
    ],
    "evidence_strength": "low",
    "confidence": 0.7399999999999999911182158029987476766109466552734375,
    "peer_reviewed_likely": "yes",
    "keywords": [
        "advanced gastric carcinoma",
        "chemotherapy",
        "hydroxycamptothecin",
        "leucovorin",
        "fluorouracil",
        "etoposide",
        "response rate",
        "toxicity",
        "myelosuppression",
        "stomatocace"
    ],
    "suggested_hubs": []
}

AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract/metadata and may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.

Comments

Log in to comment.

No comments yet.